A case of pulmonary histoplasmosis treated with voriconazole

Congyi Xie; Yimin Yang; Xiaodan Wu; Zhangzhang Chen; Na Zhu; Yuanlin Song; Lin Tong

doi:10.3855/jidc.15297

A case of pulmonary histoplasmosis treated with voriconazole

Authors

Congyi Xie Department of Pulmonary Medicine, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, Fujian, China
Yimin Yang Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Xiaodan Wu Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Zhangzhang Chen Department of Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China
Na Zhu Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
Yuanlin Song Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
Lin Tong Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China

DOI:

https://doi.org/10.3855/jidc.15297

Keywords:

Pulmonary histoplasmosis, voriconazole, immunosuppressive drugs

Abstract

Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum. The lungs are the most common site of infection, especially in patients with immune deficiency. We report a case of 62-year-old male patient presented with cough for 3 months and had been taking immunosuppressive drugs for 10 years after heart transplantation. Chest CT scan showed multiple pulmonary nodules. Lung tissue biopsy specimen culture suggested fungal infection, and Histoplasma capsulatum was confirmed by next-generation sequencing (NGS) detection. The patient was diagnosed with pulmonary histoplasmosis. After administration of voriconazole for 46 days, the symptom of cough was markedly relieved and the lesions were partly absorbed. After 13 months of treatment, the lesions completely disappeared, and no significant side-effect of voriconazole was observed. To our knowledge, report of voriconazole as the treatment of histoplasmosis is rare, especially in non-endemic areas. Moreover, this case enriches our experience in the adjustment between immunosuppressive and antifungal agents in treating histoplasmosis.

Downloads

Published

2022-03-31

How to Cite

Xie C, Yang Y, Wu X, Chen Z, Zhu N, Song Y, Tong L (2022) A case of pulmonary histoplasmosis treated with voriconazole. J Infect Dev Ctries 16:570–574. doi: 10.3855/jidc.15297

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 16 No. 03: March 2022

Section

Case Reports

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).